Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Nine Patent Applications Related to RNAi: Dec 14, 2006

Premium
Title: Intravascular Delivery of Non-Viral Nucleic Acid
 
Number: 7,148,205
 
Filed: June 20, 2003
 
Lead Inventor: Sean Monahan, Mirus Bio
 
The patent, its abstract states, covers “a process for transfecting genetic material into a mammalian cell to alter endogenous properties of the cell. The process comprises designing a polynucleotide for transfection … [then inserting the] polynucleotide … into a mammalian vessel such as a tail vein or artery. Prior to insertion, subsequent to insertion, or concurrent with insertion the permeability of the vessel is increased thereby the genetic material is delivered to the parenchymal cell altering endogenous properties of the cell,” the abstract states.
 

 
Title: Construction of Knockdown Animal by Transferring Double-Stranded RNA Expression Vector
 
Number: 20060277610
 
Filed: Oct. 29, 2003 PCT Filed: Oct. 29, 2003
 
Lead Inventor: Shunsuke Ishi
 
“This invention relates to a target gene-knockdown animal and an animal model for disease in which mRNA of an endogenous target gene is disrupted via formation of double-stranded RNA for the target gene and a method for producing the animals,” the patent application’s abstract states. “Also, this invention relates to a dsRNA expression vector used for such method and an animal cell having such vector introduced therein.”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
 
Number: 20060276635
 
Filed: Aug. 4, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”
 

 
Title: Compositions and Methods for Treatment of Prostate and Other Cancers
 
Number: 20060276424
 
Filed: June 6, 2006
 
Lead Inventor: Martin Gleave, University of British Columbia (OncoGenex)
 
According to the patent application’s abstract, “therapeutic agents which target heat shock protein 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount,” the abstract states. “The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.”
 

 
Title: Survivin-Directed RNA Interference Compositions and Methods
 
Number: 20060276423 
 
Filed: April 18, 2006
 
Lead Inventor: Rachel Altura, Columbus Children's Research Institute
 
The invention, the patent application’s abstract states, “is directed to compositions and methods for inhibiting the expression of survivin in cells expressing survivin. The invention is also directed to methods of treating conditions associated with elevated survivin, such as hyperproliferative disorders. More particularly, the invention is directed to inhibition of survivin expression using short interfering RNAs or through administration of DNA sequences yielding the expression of short hairpin RNAs.”
 

 
Title: RNA Interference-Mediated Inhibition of B7-H1 Gene Expression Using Short Interfering Nucleic Acid
 
Number: 20060276422
 
Filed: Jan. 13, 2006
 
Lead Inventor: Nassim Usman, Sirna Therapeutics
 
According to the patent application’s abstract, the invention “relates to compounds, compositions, and methods useful for modulating B7-H1 (also known as PD-L1) gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of B7-H1 gene expression and/or activity by RNA interference using small nucleic acid molecules.”
 

 
Title: Staple-Type Oligonucleotide and Drug Comprising the Same
 
Number: 20060276421
 
Filed: Sept. 29, 2004 PCT Filed: Sept. 29, 2004
 
Lead Inventor: Yasuo Kunugiza, AnGes MG
 
“Conventional oligonucleotides are opened at both ends and thereby unstable,” the patent application’s abstract states. “The stability of them against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The … invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides a staple oligonucleotides and medicaments containing the same as the active ingredient,” the abstract adds. “Specifically, it provides transcription factor inhibitors, antisense oligonucleotides and siRNAs … [as well as] agents for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischaemic diseases, worsened prognosis after organ transplantation or organ surgery, or restenosis after PTCA. … [It also] provides agents for preventing, treating or improving arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis, Crohn’s disease, chronic rheumatoid arthritis, osteoarthritis, atopic dermatitis, contact dermatitis, psoriasis, cutaneous ulcer, or decubitus.”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
 
Number: 20060275903
 
Filed: Aug. 11, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”
 

 
Title: Method of Detecting Target Base Sequence of RNA Interference, Method of Designing Polynucleotide Base Sequence Causing RNA Interference, Method of Constructing Double-Stranded Polynucleotide, Method of Regulating Gene Expression, Base Sequence Processing Apparatus, Program for Running Base Sequence Processing Method on Computer
 
Number: 20060275762
 
Filed: Nov. 21, 2003 PCT Filed: Nov. 21, 2003
 
Lead Inventor: Kaoru Saigo, Bio-Think Tank Co.
 
In the invention, the patent application’s abstract states, “a sequence segment … is searched from the base sequences of a target gene of RNA interference and, based on the search results, siRNA capable of causing RNAi is designed, synthesized, etc.”
The abstract notes that the sequence segment must meet the following requirements: The 3' end base is adenine, thymine, or uracil; the 5' end base is guanine or cytosine; a 7-base sequence from the 3' end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil; and the number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.”
 

 
Title: Potent Inhibition of Influenza Virus by Specifically Designed Short Interfering RNA
 
Number: 20060275265
 
Filed: June 2, 2006
 
Lead Inventor: Bijay Pal, California State Polytechnic University
 
According to the patent application’s abstract, the invention covers “siRNA sequences against the constant region of the influenza virus nucleoprotein gene. … The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a plasmid expressing intracellularly in animals including humans,” the abstract notes. “In another aspect, the invention includes one or more of said siRNA sequences in the form of an AAV vector adapted to express intercellularly and establish a permanent inhibitory effect against influenza virus by integrating to the cellular chromosome of animals including humans. The invention also includes the administration to an animal including humans, in a therapeutically effective amount, at least one of said siRNA sequences.”

The Scan

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.